Placebo News and Research

RSS

Antidepressant doxepin eases pain associated with oral mucositis

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.

29 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

GTx, Inc. today announced that a per protocol interim safety review on Friday, October 26, 2012, by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

29 Oct 2012

Flu shot might also prevent heart disease

Getting a flu shot may not only protect you from getting sick, it might also prevent heart disease.

29 Oct 2012

Combined antimicrobial and light therapy effective for treating foot ulcers

Results from a phase II study show that antimicrobial photodynamic therapy is significantly more effective than placebo for treating patients with chronic leg ulcers.

26 Oct 2012

Hypnosis halts hot flashes

Clinical hypnosis results in significant reductions in hot flashes compared with structured-attention control in postmenopausal women, researchers report.

26 Oct 2012

FDA approves 'first non-surgical treatment' for vitreomacular adhesion

The US Food and Drug Administration reports the approval of ocriplasmin for the treatment of symptomatic vitreomacular adhesion.

26 Oct 2012

Resveratrol does not appear to offer metabolic benefits in healthy women

Resveratrol, an ingredient in red wine thought to improve insulin sensitivity, reduce risk of heart disease and increase longevity, does not appear to offer these benefits in healthy women, new research at Washington University School of Medicine in St. Louis indicates.

26 Oct 2012

Antiviral therapy cuts progression to cancer in hepatitis

Antiviral therapy may prevent the most common form of liver cancer developing among patients who have hepatitis C-related fibrosis or cirrhosis, report researchers.

25 Oct 2012

Hypnosis can help cut hot flashes by as much as 74%

Hypnosis can help cut hot flashes by as much as 74%, shows a study supported by the National Center for Complementary and Alternative Medicine.

25 Oct 2012

Bayer announces data from riociguat Phase III trial on CTEPH

Bayer HealthCare today announced data from the Phase III CHEST-1 trial evaluating its investigational drug riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent pulmonary hypertension (PH) after surgery.

24 Oct 2012

Probiotic supplementation improves health-related quality of life during common cold

College students are notoriously sleep-deprived, live in close quarters and lead stress-filled lives, making them especially susceptible for contracting colds and upper-respiratory infections. For these reasons, a team lead by researchers at the University of Medicine and Dentistry of New Jersey-School of Health Related Professions (UMDNJ-SHRP) selected this population to study the effects of probiotic supplementation on health-related quality of life (HRQL) during the common cold.

24 Oct 2012

Antipsychotic drug quandary for Alzheimer’s patients

Stopping treatment with risperidone to limit side effects risks the return of psychosis or agitation in patients with Alzheimer’s disease who have been taking the drug to suppress such symptoms, research shows.

23 Oct 2012

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA (adalimumab) ULTRA 1 and ULTRA 2 studies.

23 Oct 2012

Possible overlap exists between inflammatory bowel disease and IBS

Research unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas suggests a possible overlap of symptoms of two prevalent GI disorders: irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) and further suggests a possible link between subtle GI tract inflammation and IBS symptoms-a link that is also the focus of the first systemic review of the literature on this topic and an editorial both published in this month's American Journal of Gastroenterology.

23 Oct 2012

Eisai receives FDA approval for Fycompa to treat partial onset seizures

The U.S. Food and Drug Administration today approved Fycompa (perampanel) tablets to treat partial onset seizures in patients with epilepsy ages 12 years and older.

23 Oct 2012

Multivitamin use may protect men from cancer

Men who take a daily multivitamin supplement have a modest reduction in their risk for developing cancer, suggest results from the Physicians’ Health Study II.

22 Oct 2012

$Ustekinumab success in refractory Crohn’s disease$

Ustekinumab success in refractory Crohn’s disease

Patients with Crohn’s disease who have failed to respond adequately to anti–tumor necrosis factor treatment may benefit from the monoclonal antibody ustekinumab, results of a double-blind, placebo-controlled trial suggest.

22 Oct 2012

Rhythm presents RM-131 Phase 1 clinical trial results for diabetic gastroparesis at ACG 2012

Rhythm announced today the results of two Phase 1 clinical trials of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis, which demonstrated that RM-131 greatly accelerates gastric emptying in healthy subjects with good tolerability.

22 Oct 2012

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Chinese herbs, including JHQG, BFXL, and BFHX, may show significant benefits for patients with non-small cell lung cancer (NSCLC), idiopathic pulmonary fibrosis (IPF), and influenza.

22 Oct 2012